Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Work or School Clearance Persons with newly positive TSTs or IGRAs may be cleared for work or school if they are low risk by history, asymptomatic and have a negative chest radiograph. Persons with prior positive TSTs may be cleared if they have a negative history and are asymptomatic. Periodic chest radiographs are NOT indicated unless persons with prior positive TSTs or IGRAs are symptomatic for TB. Use the Tuberculosis Screening Questionnaire / Chest X-ray Interpretation Request (18.1) to complete history and symptom screening. If history, symptom screening and chest x-ray are negative, the patient may be cleared for work or school by the PHN or provider. Complete the Tuberculosis Screening and Clearance Card to document clearance. . Tuberculosis Screening and Clearance cards can be ordered from the Alaska TB Program by calling 907-269-8000. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis of Latent Tuber culosis Infection 7 . 20 R e v i s e d N o v e m b e r 2 0 1 2
Resources and References Resources ATS, CDC, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at: http://www.cdc.gov/tb/pubs/PDF/1376.pdf . CDC. Core Curriculum on Tuberculosis (2011) [Division of Tuberculosis Elimination Web site]. Updated 2011. Available at: http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm CDC. Self-Study Modules on Tuberculosis (Division of Tuberculosis Elimination Web site; 2008). Available at: http://www.cdc.gov/tb/education/ssmodules/default.htm References 1 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):15. 2 CDC. Classification system. In: Chapter 2: transmission and pathogenesis. Core Curriculum on Tuberculosis (2004) [Division of Tuberculosis Elimination Web site]. Updated October 2004. Available at: . http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010. 3 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):4-5 4 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):1–2. 5 CDC.Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010 (MMWR 2010; 59 [No. RR-5];1-25) at http://www.cdc.gov/mmwr/PDF/rr/rr5905.pdf 6 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):11; CDC, NTCA. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15):13; County of Los Angeles Tuberculosis Control Program. Tuberculosis Control Program Manual: 2003 Edition:2-1. Available at: http://www.lapublichealth.org/tb/TBManual/TBmanual.pdf . Accessed February 6, 2007. 7 Curry International Tuberculosis Center. Diagnosis and treatment [Web page]. Available online at: http://currytbcenter.ucsf.edu/abouttb/diagnosis_and_treatment.cfm Accessed October28, 2011. 8 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):1–2. 9 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):49. 10 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):50. 11 CDC. Candidates for treatment of latent TB infection. In: Chapter 5: treatment of LTBI. Core Curriculum on Tuberculosis (2011). Updated 2011. ) [Division of Tuberculosis Elimination Web site]. Available at: . http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010. 12 CDC. Tuberculin skin testing. In: Chapter 3: testing for TB disease and infection. Core Curriculum on Tuberculosis (2011). Updated 2011. ) [Division of Tuberculosis Elimination Web site]. Available at: . http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010. 13 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):53. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis of Latent Tuber culosis Infection 7 . 21 R e v i s e d N o v e m b e r 2 0 1 2
- Page 101 and 102: † 4 Table 4: DOSES*OF FIRST-LINE
- Page 103 and 104: Figure 1:TREATMENT ALGORITHM FOR DR
- Page 105 and 106: a. In remote locations in Alaska, m
- Page 107 and 108: Antituberculosis Drug Rifampin (RIF
- Page 109 and 110: Antituberculosis Drug Rifapentine (
- Page 111 and 112: Reporting Reactions The table below
- Page 113 and 114: Response to Treatment For consultat
- Page 115 and 116: Figure 2: MANAGEMENT OF TREATMENT I
- Page 117 and 118: Post-Treatment Evaluation Routine f
- Page 119 and 120: Treatment in Special Situations Tre
- Page 121 and 122: Resources For consultation regardin
- Page 123 and 124: with an increase in overall complet
- Page 125 and 126: Liver Disease Management of TB in p
- Page 127 and 128: After the initial phase (first two
- Page 129 and 130: Extrapulmonary Tuberculosis The bas
- Page 131 and 132: Resources and References Resources
- Page 133 and 134: Diagnosis of Latent Tuberculosis In
- Page 135 and 136: Forms All required and recommended
- Page 137 and 138: High-Risk Groups Certain factors id
- Page 139 and 140: Diagnosis of Latent Tuberculosis In
- Page 141 and 142: continually exposed to populations
- Page 143 and 144: Administration of the Tuberculin Sk
- Page 145 and 146: See “Two-Step Tuberculin Skin Tes
- Page 147 and 148: See “Live-Virus Vaccines” under
- Page 149 and 150: For more information on IGRAs and t
- Page 151: Table 5: TARGETED TESTING FOR LATEN
- Page 155 and 156: Treatment of Latent Tuberculosis In
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177 and 178: Medication Administration and Pharm
- Page 179 and 180: National Tuberculosis Controllers A
- Page 181 and 182: 24 CDC . “Recommendations for Use
- Page 183 and 184: Diagnosis and Treatment of Latent T
- Page 185 and 186: All children suspected or diagnosed
- Page 187 and 188: Latent Tuberculosis Infection (LTBI
- Page 189 and 190: History of BCG vaccination is not a
- Page 191 and 192: Because of their higher specificity
- Page 193 and 194: Table 3: COUNTRIES AND AREAS WITH A
- Page 195 and 196: Treatment of Latent TB Infection (L
- Page 197 and 198: For consultation regarding the trea
- Page 199 and 200: Monitoring DOT is mandatory for INH
- Page 201 and 202: For young infants, some experts rec
Work or School Clearance<br />
Persons with newly positive TSTs or IGRAs may be cleared for work or school if they are<br />
low risk by history, asymptomatic and have a negative chest radiograph. Persons with<br />
prior positive TSTs may be cleared if they have a negative history and are<br />
asymptomatic. Periodic chest radiographs are NOT indicated unless persons with prior<br />
positive TSTs or IGRAs are symptomatic for TB.<br />
Use the <strong>Tuberculosis</strong> Screening Questionnaire / Chest X-ray Interpretation<br />
Request (18.1) to complete history and symptom screening. If history,<br />
symptom screening and chest x-ray are negative, the patient may be<br />
cleared for work or school by the PHN or provider. Complete the<br />
<strong>Tuberculosis</strong> Screening and Clearance Card to document clearance. .<br />
<strong>Tuberculosis</strong> Screening and Clearance cards can be ordered from the<br />
<strong>Alaska</strong> TB <strong>Program</strong> by calling 907-269-8000.<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis <strong>of</strong> Latent Tuber culosis Infection 7 . 20<br />
R e v i s e d N o v e m b e r 2 0 1 2
Change language